Abstract-The intracellular action on exocytosis of botulinim A toxin and constituent chains was studied using permeabilized isolated nerve endings from the rat neural lobe. The release of the neuropeptide vasopressin was measured by radioimmunoassay. In the presence ofthe reducing agent dithiothreitol, the two-chain form of botulinum A toxin inhibited vasopressin release induced by 10 Jl M free calcium. Half maximal inhibition was obtained with 15 nM botulinum A toxin. In the absence of the heavy chain the light chain of the toxin strongly inhibited exocytosis with a half maximal effect of 2.5 nM. The inhibitory effects on secretion could be prevented by incubating the light chain with an immune serum against botulinum A toxin. The heavy chain of botulinum A toxin did not affect vasopressin release. However, it prevented the inhibitory effects of the light chain on stimulated exocytosis.
Botulinum A toxin belongs to a family of cIosely reIated neurotoxins. The 150,000 mol. wt protein consists of a heavy chain (100,000 mol. wt) and a light chain (50,000 mol. wt) covalently linked by a disulfide bond. It inhibits neuro transmission at the peripheral cholinergic nerve endings by inhibiting neurotransmitter release. A three-step model is thought to produce the paralytic effects. It consists of (i) extracellular binding, (ii) internalization and (iii) intracellular poisoning (cf. Refs 12 and 19) . The toxins' effects are restricted to the nervous tissue when given extracellularly. However, an extracellular application does not allow the differentiation of the intracellular processes involved in the final inhibition of transmitter release and the role played by the individual chains of the toxin.
Recently, using cultured adrenal chromaffin cells permeabilized with streptolysin 0, it has been shown that intracellularly applied botulinum A toxin is more effective in the presence of a reducing agent. Indeed, the light chain of botulinum A toxin alone inhibited Ca 2 + -stimulated catecholamine release. 5 ,20,21 In contrast, both the heavy and the light chain must be tPresent address: Centre de Neurochirnie du CNRS, 5 rue Blaise Pascal, F-67084 Strasbourg, France. Abbreviations: AVP, arginine vasopressin; DTT, dithiothreitol; EGTA, ethyleneglycol-bis(ß -amino-ethylether)N,N'-tetraacetic acid; HEPES, N-2-hydroxyethylpiperazine-N'-2-ethane sulfonic acid; PIPES, piperazine-N,N'-bis-(2-ethane sulfonic acid).
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present in Aplysia neurons to inhibit transmitter release. 16 So far it is unknown whether these discrepancies are due to a general difference in the exocytotic mechanism in neurons as compared to endocrine cells or to differences between molluscs and mammals.
To address some of these questions, the nerve terminals isolated from the rat neural lobe were used as a mammalian neuronal system. These nerve endings represent a potent tool for studying the mechanism of stimulus-secretion coupling.
14 They can be successfully permeabilized with digitonin and addition of micromolar amounts of Ca 2 + are then sufficient to elicit neurohormone release. 9 This process requires magnesium and chloride ions but not exogenous A TP.
IO The permeabilized nerve terminals survive even prolonged incubations and are therefore suitable for studies with the slowly acting neurotoxins.
EXPERIMENTAL PROCEDURES

Preparation 0/ isolated neurosecretory nerve terminals
The neural lobes were isolated from male Wistar rats (Charles River, Sulzfeld, F.R.G.) weighing 250--300 g and washed with normal Locke saline containing (in mM): NaCI (140); KHC0 3 (5); MgCI 2 (I); CaCI 2 (2.2); Tris-HEPES (10); glucose (10); bovine serum albumin (Miles) 0.025%, pH 7.25. The medium was then replaced by a buffer containing 270 mM sucrose, 10 mM Tris-HEPES, 2 mM EGTA instead of 0.01 mM EGTA as described previously. 8 The nerve endings were then isolated as described 8 with some minor modifications. Briefly, the neurohypophyses were homogenized in the buffered sucrose solution and centrifuged at 100 g for Imin. The supernatant was taken and centrifuged again at 2400 g for 5 min. The pellet contains mostly isolated nerve endings as judged by electron microscopy.15 Throughout the isolation procedure and the experiment the temperature was maintained at 37°C. The nerve endings were then resuspended in normal Locke solution and loaded onto 0.20 jlm Gelman filters (Acro, LC 13) and perfused as given below.
Superfusion of the isolated nerve endings
The isolated nerve endings were perfused by means of a multichannel peristaltic pump (Ismatec IPN 8) for 60 min with normal Locke at a flow rate of 50 jll/min which was then increased to 100 jll/min until the end of the experiment. The perfusion was further continued with normal Locke containing no Ca2+ but 5 mM EGT A for 10 min. The medium was then replaced by K + -glutamate buffer (medium B) containing (in mM): K + -glutamate (130); MgCl 2 (2); EGTA (5); glucose (10); PIPES [piperazine-N,N'-bis(2-ethane sulfonic acid)] (20); bovine serum albumin 0.025%, pH 6.8 and perfusion-run for a further 30 min. For permeabilization, the nerve endings were perfused for 5 min with IIlM digitonin in medium B. Subsequently, the terminals were perfused for 25 min with the various forms of botulinum A toxin dissolved in medium B supplemented with I mM dithiothreitol (DTT). Stimulation was performed for 10 min with medium B supplemented with 10 Il M free Ca2+. Collection of the perfusate by means of a ffaction collector (Gilson-203) started 130 min after loading, i.e. 6 min before the Cal+ stimulation. Fractions were collected every 2 min and immediately frozen until radioimmunoassay for released arginine vasopressin (A VP) was performed. 1 The Ca2+ evoked hormone release was calcula ted by subtracting the mean basal release determined in the fractions preceding the onset of the Ca 2 + stimulus from the amount of hormone found in each of the following eight fractions. 8 Free Ca2+ concentrations were calculated using the stability constants listed 18 and measured with a Cal+-sensitive electrode 4 as described recently.11
Materials
Botulinum A toxin (two-chain form), as obtained from Batelle Institute, Frankfurt, F.R.G., was homogeneous on SDS gel electrophoresis. It was separated into its heavy and light chain by high performance liquid chromatography anion exchange chromatography using a modification of the low performance liquid chromatography procedure described. 17 All steps were performed at 18°C at pH 8.4 (adjusted with NaOH). Typically 600 Ilg (I ml) botulinum A toxin was first desalted on a Econo-Pac IOGD (Bio-Rad) column and then applied to a Mono Q 5/5 (Pharmacia-LKB) co!umn both equilibrated with buffer I containing (in mM): Na 2 B.o 7 (7.5) and NaH 2 PO. (15) . The Mono Q column was washed with 6 ml of buffer. For chain separation 50 mM DTT dissolved in 1.5 ml ofbuffer I was applied to the column and the fiow was stopped for 2 h. The light chain was then eJuted at a rate of 0.25 ml/min with 7.5 ml of a mixture of nine parts buffer II (buffer II supplemented with 2 M urea and 50 mM DTT) and one part of buffer III containing (in mM): Na 2 B.0 1 (75); NaH 2 PO. (ISO); urea (2000); DTT (50). The absorbed heavy chain was finally eluted from the column with 7.5 ml of buffer IH. Fractions were collected and the chains were located using a protein assay.6 Immediately after separation the chains were dialysed against a K-glutamate buffer containing (in mM): K + -glutamate (J 50); PIPES (10); EGTA (0.5); nitrilotriacetic acid (5), pH 7.2 supplemented with I or 5 mM DTT. Toxicity (w so , s.c. in mice) was I ng/kg for the two-chain form and between land 5 jlgjkg for the separated heavy or light chains, respectively. Botulinum A antitoxin, an immune serum from horse cg 750 lU/mi, was obtained from Behring Werke Marburg, F.R.G., and dialysed against K-glutamate buffer before use.
RESULTS
When added to permeabilized neurosecretory nerve terminals the two-chain form of botulinum A toxin decreased the Ca 2 + -evoked vasopressin release within 25 min. Inhibition started at botulinum A toxin concentrations below 5 nM. The presence of a reducing agent, DTT, was required for the inhibitory effect of the two-chain form of botulinum A toxin. In the absence of DTT almost no inhibition occurred. Fifty per cent inhibition was achieved with around 15 nM toxin (Fig. 1) .
The isolated light chain of botulinum A toxin alone is fully active in these permeabilized nerve endings (Fig. 2) . Incubation for aperiod of 25 min in the absence of free Ca 2 + reduced the basal release only slightly. However, compared to the controls, the Ca 2 + -induced AVP release was strongly inhibited by the botulinum A toxin. The permeabilized terminals did not respond to a second Ca 2 + challenge given after 50 min washout with Ca 2 + -free solution. This indicates that the effect of botulinum A toxin light chain was irreversible. Under the same conditions the controls fully responded to Ca2+ (Fig. 2) .
The inhibitory effect of botulinum A toxin light chain on stimulated A VP release could be fully overcome by preincubating the light chain with an immune serum against botulinum A toxin, indicating its specific action. The antiserum itself did not interfere with the basal or evoked A VP release (Fig. 3) .
In order to find out whether the light chain alone is responsible for the observed effects or whether the heavy chain modifies the action of light chain, light and heavy chains were applied simultaneously. Interestingly, the combined addition of the two chains either applied in equimolar concentrations (Fig. 4a) or with a ten-fold excess of the heavy chain (Fig. 4b) overcame the inhibitory action of 1 nM light chain (Fig. 4a,b) . The heavy chain alone did not alter basal or evoked AVP release (Fig. 4a,b) . This result (cf. Fig. I with Fig. 4) . Thus, the heavy chain of botulinum A toxin does not contribute to the intracellular action of the light chain but rather inhibits it. Figure 5 gives the dose-response curve of the inhibitory action of the light chain of botulinum A toxin on evoked A VP release from permeabilized nerve terminals. The inhibition started below a light chain concentration of 1 nM. The evoked A VP release was inhibited by 50% after application of 2.5 nM light chain for 25 min preceding the stimulation (Fig. 5) .
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Even higher doses of the light chain did not give complete inhibition of A VP release. This observation is in agreement with the situation seen in permeabilized chromaffin cells. 21 
DISCUSSION
The regulation of neurotransmitter release from mammalian synaptic terminals is poorly understood. Neurohypophysial nerve endings are an exception because they can be permeabilized and the intraterminal regulation of exocytosis can be analysed.
• 14
We have used them to investigate the mechanism of neurotoxin action focussing on clostridial neurotoxins.
•
19 Here we present the first report upon intracellular effects of botulinum A toxin in a mammalian neuron.
We found that the two-chain form ofbotulinum A toxin is more effective in the presence of a reducing agent, suggesting that the disulfide bridge which links the heavy and the light chain has to be cleaved before exocytosis is inhibited. More importantly, the light chain alone is fully active and more potent in inhibiting neurohormone release as compared to the reduced two-chain form. The action of botulinum A toxin in permeabilized nerve terminals is in line with recent observations on streptolysin 0 permeabilized bovine adrenal chrom affin cells. 20 . 21 In these neuroendocrine cells reductive conditions enhance the inhibitory effect on catecholamine secretion of the two-chain form of botulinum A toxin. 20 Furthermore, the light chain alone is fully active.
.
21
The da ta also fit with a more general concept of clostridial neurotoxin processing. The primary gene product, a single chain form, has to be cleaved proteolytically and this is followed by a reduction of the interchain disulfide bond. As a consequence the light chain is activated. Recent results obtained with the closely related tetanus toxin in permeabilized adrenal chromaffin and pel2 cells are along this line. The single chain form is ineffective, the potency ofthe two-chain form is increased by a reducing agent and the light chain alone is fully inhibitory.I-3
Once in a cytosolic compartment the heavy chain which may be necessary for internalization is no Ion ger required for full activity of the light chain. Moreover, if heavy and light chains are simultaneously present they are less active than the light chain alone. Again the situation resembles the one seen within chromaffin cells. Here the heavy chain does not change or rat her reduces the potency of the light chains of botulinum A toxin 21 or tetanus toxin. ' By contrast, in invertebrate neurons, such as those of the buccal ganglia of Aplysia, the roles of the chains are different. When directly injected into the neuron the light chain of botulinum A toxin is not active on its own but requires the presence of a heavy chain. 16 The presence of both chains of botulinum A toxin is unique since the light chain of tetanus toxin alone inhibits neurotransmitter release in Aplysia neurons. 13 The differences in botulinum A toxin action between Aplysia neurons and mammalian neuronal or chrom affin cells needs further investigation. One important difference to the mammalian systems is the high osmolarity of the medium required for studies with Aplysia neurons. Tilis might alter the conformation of the light chain of botulinum A toxin or its target. The addition ofthe heavy chain may then help the light chain to become effective. However, it is not excluded that the exocytosis of the large granules from mammalian nerve terminals and that of small synaptic vesicles from Aplysia neurons is regulated differently.
Taken together the da ta presented here and those already published suggest that botulinum A toxin by its light chain attacks a step during exocytosis which is common to mammalian neurons and chromaffin cells. The precise localization of its attack, probably the vesicular or the plasma membrane, remains to be found. assistanee and Dr John Bicknell (Babraham, Cambridge, U.K.) for AVP antiserum. G. Dayanithi is a fellow of the Alexander von Humboldt Foundation, F.R.G. This work was supported by the Deutsche Forschungsgemeinschaft (Gr 681), the Sonderforschungsbereich 249, and grants from INSERM and CNRS, France.
